Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $45.21 USD
Change Today -0.23 / -0.51%
Volume 235.8K
BABY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

natus medical inc (BABY) Snapshot

Open
$45.46
Previous Close
$45.44
Day High
$46.70
Day Low
$45.08
52 Week High
07/23/15 - $46.98
52 Week Low
08/21/14 - $27.00
Market Cap
1.5B
Average Volume 10 Days
292.0K
EPS TTM
$1.19
Shares Outstanding
33.0M
EX-Date
--
P/E TM
38.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for NATUS MEDICAL INC (BABY)

Related News

No related news articles were found.

natus medical inc (BABY) Related Businessweek News

No Related Businessweek News Found

natus medical inc (BABY) Details

Natus Medical Incorporated designs, manufactures, and markets newborn care and neurology healthcare products and services worldwide. It offers healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The company’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. Its neurology products comprise diagnostic electroencephalography and long-term monitoring products, electrodiagnostic monitoring products, diagnostic polysomnography monitoring products, diagnostic intraoperative monitoring products, and transcranial Doppler products. The company’s newborn care products include hearing screening products to screen the hearing in the newborn; brain injury products to diagnose the severity of brain injury, monitor the effectiveness of drug therapies, detect seizure activity and monitor general neurological status; and thermoregulation products to control the newborn environment, including incubators and warmers. Its newborn care products also comprise jaundice management products to measure bilirubin levels and treat jaundice; diagnostic hearing assessment products to screen for or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems in patients of all ages; and balance and mobility systems to diagnose and assist in treating balance disorders. The company serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was founded in 1987 and is headquartered in Pleasanton, California.

948 Employees
Last Reported Date: 03/16/15
Founded in 1987

natus medical inc (BABY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $650.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $365.0K
Vice President and General Manager of Neurolo...
Total Annual Compensation: $295.0K
Vice President and General Manager of Newborn...
Total Annual Compensation: $295.0K
Vice President of Medical Affairs, Quality & ...
Total Annual Compensation: $267.0K
Compensation as of Fiscal Year 2014.

natus medical inc (BABY) Key Developments

Natus Medical Incorporated Announces Unaudited and Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Third Quarter of 2015; Revises Earnings Guidance for the Full Year of 2015

Natus Medical Incorporated announced unaudited and consolidated financial results for the second quarter and six months ended June 30, 2015. For the second quarter, the company reported revenue of $91,937,000 against $86,325,000 reported for the second quarter of 2014. Income from operations was $14,002,000 against $9,945,000 a year ago. Income before tax was $13,622,000 against $10,740,000 a year ago. Net income was $9,851,000 or $0.30 diluted earnings per share against $7,461,000 or $0.23 diluted earnings per share a year ago. Non-GAAP income before provision for income tax was $16,640,000 against $12,264,000 for the same period in the last year. Non-GAAP net income was $11,158,000 or $0.34 diluted earnings per share against $8,928,000 or $0.28 diluted earnings per share for the same period in the last year. Non-GAAP Operating profit $17,020,000 against $11,469,000 for the same period in the last year. For six months, the company reported revenue of $181,332,000 against $171,948,000 reported for the second quarter of 2014. Income from operations was $27,348,000 against $19,332,000 a year ago. Income before tax was $26,138,000 against $20,439,000 a year ago. Net income was $18,447,000 or $0.56 diluted earnings per share against $14,216,000 or $0.44 diluted earnings per share a year ago. Non-GAAP income before provision for income tax was $30,949,000 against $24,269,000 for the same period in the last year. Non-GAAP net income was $21,431,000 or $0.65 diluted earnings per share against $17,219,000 or $0.53 diluted earnings per share for the same period in the last year. Non-GAAP Operating profit $32,159,000 against $23,162,000 for the same period in the last year. The company provided revenue and earnings guidance for the third quarter and increased its earnings guidance for the full year 2015. For the third quarter of 2015, the company expects revenue of $93.0 million to $94.0 million and non-GAAP earnings per share of $0.37 to $0.38. The company increased its non-GAAP earnings guidance for the full year 2015 and expects to report non-GAAP earnings per share of $1.50 to $1.52, an increase from previous guidance of $1.47 to $1.51. Full year 2015 revenue guidance was unchanged at $376 million to $378 million.

Natus Medical Inc. to Report Q2, 2015 Results on Jul 22, 2015

Natus Medical Inc. announced that they will report Q2, 2015 results at 9:00 AM, Eastern Standard Time on Jul 22, 2015

Natus Medical Inc., Q2 2015 Earnings Call, Jul 22, 2015

Natus Medical Inc., Q2 2015 Earnings Call, Jul 22, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BABY:US $45.21 USD -0.23

BABY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NeuroMetrix Inc $0.78 USD +0.009
Oxford Instruments PLC 913.00 GBp +3.00
View Industry Companies
 

Industry Analysis

BABY

Industry Average

Valuation BABY Industry Range
Price/Earnings 40.8x
Price/Sales 4.0x
Price/Book 3.9x
Price/Cash Flow 39.2x
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NATUS MEDICAL INC, please visit www.natus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.